Want to see IN:SOLARA full AI Analyst Report?
SOLARA Stock Chart & Stats
₹490.35
₹13.05(2.65%)
At close: 4:00 PM EDT
₹490.35
₹13.05(2.65%)
Day’s Range― - ―
52-Week Range₹422.85 - ₹711.20
Previous CloseN/A
Volume579.03K
Average Volume (3M)37.94K
Market Cap
₹24.50B
Enterprise Value₹33.31K
Total Cash (Recent Filing)₹533.40M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding47,784,080
10 Day Avg. Volume26,889
30 Day Avg. Volume37,944
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.50
Price to Sales (P/S)1.37
P/FCF Ratio211.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)31.4
Revenue Forecast (FY)₹17.95B
Bulls Say, Bears Say
Bulls Say
API & CDMO Business ModelSolara’s core API and CDMO model yields diversified, B2B revenue streams and recurring supply relationships with drugmakers. Scale manufacturing, regulatory know‑how and service offerings support durable demand from global pharma customers and reduce reliance on any single product.
Revenue Recovery & Operating ProfitA return to revenue growth (+13.5% in FY2026) alongside restored operating profitability over FY2025–FY2026 indicates improved commercial execution and cost control. If sustained, this trend supports more predictable operating cash generation and validates capacity to convert sales into recurring operating earnings.
Improving LeverageMaterial reduction in debt-to-equity enhances financial flexibility and lowers refinancing risk for a capital-intensive API manufacturer. Improved leverage frees capacity for selective capex, customer qualification investments and cushions the business during industry cycles, supporting longer-term stability.
Bears Say
Volatile Gross MarginsA dramatic gross margin swing (~51% down to ~27%) points to material exposure to pricing pressure, adverse product mix shifts or cost inflation. Such volatility impairs margin predictability and makes it harder to sustainably translate revenue into profit, complicating long-term planning.
Weak Cash GenerationOperating cash flow and free cash flow deterioration (FCF down ~80% to 88.8m) signals poor cash conversion and potential working-capital stress. Persistent cash volatility constrains the company’s ability to self-fund capex, service debt, pursue R&D or sustain investments required for long-term customer retention.
Net Loss & Weak ReturnsDespite operating profit improvements, a FY2026 net loss and negative returns to shareholders indicate inconsistent bottom-line performance. Continued net losses or marginal profitability reduce retained earnings, hinder capital allocation flexibility, and may limit confidence for long‑term investors and partners.
Solara Active Pharma Sciences Ltd. News
SOLARA FAQ
What was Solara Active Pharma Sciences Ltd.’s price range in the past 12 months?
Solara Active Pharma Sciences Ltd. lowest stock price was ₹422.85 and its highest was ₹711.20 in the past 12 months.
What is Solara Active Pharma Sciences Ltd.’s market cap?
Solara Active Pharma Sciences Ltd.’s market cap is ₹24.50B.
When is Solara Active Pharma Sciences Ltd.’s upcoming earnings report date?
Solara Active Pharma Sciences Ltd.’s upcoming earnings report date is Nov 11, 2026 which is in 100 days.
How were Solara Active Pharma Sciences Ltd.’s earnings last quarter?
Solara Active Pharma Sciences Ltd. released its earnings results on Jul 23, 2026. The company reported ₹3.52 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Solara Active Pharma Sciences Ltd. overvalued?
According to Wall Street analysts Solara Active Pharma Sciences Ltd.’s price is currently Overvalued.
Does Solara Active Pharma Sciences Ltd. pay dividends?
Solara Active Pharma Sciences Ltd. pays a Notavailable dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Solara Active Pharma Sciences Ltd. dividends here
What is Solara Active Pharma Sciences Ltd.’s EPS estimate?
Solara Active Pharma Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solara Active Pharma Sciences Ltd. have?
Solara Active Pharma Sciences Ltd. has 47,784,080 shares outstanding.
What happened to Solara Active Pharma Sciences Ltd.’s price movement after its last earnings report?
Solara Active Pharma Sciences Ltd. reported an EPS of ₹3.52 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.12%.
Which hedge fund is a major shareholder of Solara Active Pharma Sciences Ltd.?
Currently, no hedge funds are holding shares in IN:SOLARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solara Active Pharma Sciences Ltd.
Solara Active Pharma Sciences Limited is an Indian-based pharmaceutical company primarily involved in the comprehensive development, production, and global trade of active pharmaceutical ingredients (APIs). Their activities span the manufacturing, processing, sale, import, and export of these essential drug components. The company's extensive product range includes APIs designed for a wide spectrum of therapeutic applications, such as anesthetics, antibiotics, antivirals, cardiovascular agents, central nervous system treatments, anti-inflammatory drugs, and treatments for metabolic disorders like type-II diabetes, among numerous other specialized categories. Beyond its core product offerings, Solara also delivers specialized contract research and manufacturing services (CRAMS) for APIs. These services encompass custom development and manufacturing, analytical support, impurity synthesis, and comprehensive regulatory assistance. The company maintains a significant international presence, exporting its products and conducting operations across diverse global regions, including the Asia Pacific, Europe, North America, and South America. Headquartered in Chennai, India, Solara Active Pharma Sciences Limited was established in 2017. Initially known as SSL Pharma Sciences Limited, the company adopted its current name in March of the same year.
Technical Analysis
Granules India Limited
―
Hikal Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Strides Pharma Science Ltd
―
Unichem Laboratories Limited
―